litlas
Log inCreate account

Sara A. Hurvitz

Active 2008–2025

171
Papers
28,609
Citations
77
h-index
162
i10-index

Citations

Citations per year for Sara A. Hurvitz1964: 1 citations1982: 2 citations1993: 3 citations1997: 1 citations1999: 3 citations2009: 1 citations2010: 12 citations2011: 17 citations2012: 44 citations2013: 60 citations2014: 70 citations2015: 70 citations2016: 98 citations2017: 113 citations2018: 144 citations2019: 675 citations2020: 1,115 citations2021: 1,325 citations2022: 1,555 citations2023: 1,611 citations2024: 2,585 citations2025: 1,416 citations2026: 41 citations1965–1981: no citations, so these years are not shown1983–1992: no citations, so these years are not shown1994–1996: no citations, so these years are not shown1998: no citations, so this year is not shown2000–2008: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,962 citing papers, 23.1% of this breakdownChina: 1,458 citing papers, 11.4% of this breakdownItaly: 925 citing papers, 7.2% of this breakdownUnited Kingdom: 651 citing papers, 5.1% of this breakdownFrance: 627 citing papers, 4.9% of this breakdownGermany: 604 citing papers, 4.7% of this breakdownSpain: 580 citing papers, 4.5% of this breakdownJapan: 377 citing papers, 3% of this breakdownCanada: 374 citing papers, 2.9% of this breakdownSwitzerland: 349 citing papers, 2.7% of this breakdownBelgium: 317 citing papers, 2.5% of this breakdownSouth Korea: 312 citing papers, 2.5% of this breakdown
0%23.1%Other 25.5%

Institutions

Fields

  • Medicine65.1%
  • Biochemistry, Genetics and Molecular Biology28%
  • Immunology and Microbiology2.2%
  • Materials Science1.1%
  • Computer Science0.9%
  • Engineering0.7%
  • Other2%

Topics

  • HER2/EGFR in Cancer Research10.1%
  • Advanced Breast Cancer Therapies8.9%
  • Breast Cancer Treatment Studies5.6%
  • Monoclonal and Polyclonal Antibodies Research3.8%
  • PARP inhibition in cancer therapy3.1%
  • Cancer Treatment and Pharmacology3.1%
  • Other65.4%

Coauthors

All papers

Open in search
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 cited by 1,543

  2. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Authors: Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung‐Bae Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock‐Ah Im, Keun Seok Lee, Sara A. Hurvitz, Javier Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian E. Krop - New England Journal of Medicine 2019 cited by 1,973

  3. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

    Authors: Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck - Annals of Oncology 2021 cited by 1,367

  4. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    Authors: Javier Cortés, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Chiun-Sheng Huang, Jee Hyun Kim, Joanne W.Y. Chiu, Jose Luiz Pedrini, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz - New England Journal of Medicine 2022 cited by 1,124

  5. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    Authors: Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, Seock‐Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altıntaş, Jan‐Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Sung‐Bae Kim, Vanessa Petry, Chiun‐Sheng Huang, Wěi Li, Jean‐Sébastien Frenel, Silvia Antolín, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés - The Lancet 2022 cited by 642

  6. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

    Authors: Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martín, Henri Roché, Young‐Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia Cristina Tudor, Alison L. Hannah, W. Eiermann, Joanne L. Blum - New England Journal of Medicine 2018 cited by 2,151

  7. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2022 cited by 964

  8. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana G. Abramson, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Bryan P. Schneider, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Jessica Young, Kay T. Yeung, Mary A. Dwyer, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2023 cited by 440

  9. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Authors: Debu Tripathy, Seock‐Ah Im, Marco Colleoni, Fábio Franke, Aditya Bardia, Nadia Harbeck, Sara A. Hurvitz, Louis W.C. Chow, Joohyuk Sohn, Keun Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung Hae Jung, Govind Babu, Paul Wheatley‐Price, Michelino De Laurentiis, Young‐Hyuck Im, Sherko Küemmel, Nagi S. El-Saghir, Mei-Ching Liu, Gary P. Carlson, Gareth Hughes, Iván Díaz-Padilla, Caroline Germa, Samit Hirawat, Yen‐Shen Lu - The Lancet Oncology 2018 cited by 1,011

  10. Cycling cancer persister cells arise from lineages with distinct programs

    Authors: Yaara Oren, Michael Tsabar, Michael S. Cuoco, Liat Amir-Zilberstein, Heidie Frisco Cabanos, Jan-Christian Hütter, Bomiao Hu, Pratiksha I. Thakore, Marcin Tabaka, Charles P. Fulco, William Colgan, Brandon M. Cuevas, Sara A. Hurvitz, Dennis J. Slamon, Amy Deik, Kerry A. Pierce, Clary B. Clish, Aaron N. Hata, Elma Zaganjor, Galit Lahav, Katerina Politi, Joan S. Brugge, Aviv Regev - Nature 2021 cited by 516

  11. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Authors: Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fábio Franke, Louis W.C. Chow, Joohyuk Sohn, Keun-Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung-Hae Jung, Arunava Chakravartty, Gareth Hughes, Ioannis Gounaris, Karen Rodriguez-Lorenc, Tetiana Taran, Sara A. Hurvitz, Debu Tripathy - New England Journal of Medicine 2019 cited by 1,021

  12. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    Authors: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 cited by 357

  13. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    Authors: Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Ming‐Shen Dai, Shang-Wen Chen, Sara A. Hurvitz, Sung‐Bae Kim, Beverly Moy, Suzette Delaloge, William J. Gradishar, Norikazu Masuda, Markéta Palácová, Maureen Trudeau, Johanna Mattson, Yoon Sim Yap, Ming‐Feng Hou, Michelino De Laurentiis, Yu‐Min Yeh, Hong‐Tai Chang, Thomas Yau, Hans Wildiers, Barbara Haley, Daniele Fagnani, Yen‐Shen Lu, John Crown, Johnson Lin, Masato Takahashi, Toshimi Takano, Miki Yamaguchi, Takaaki Fujii, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 cited by 609

  14. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Authors: Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz - Annals of Oncology 2021 cited by 299

  15. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    Authors: Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer - Journal of Clinical Oncology 2020 cited by 549

  16. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Authors: Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina, Hope S. Rugo, Ki Hoon Lee, Anthony Gonçalvès, Sami Diab, Natasha Woodward, Annabel Goodwin, Rinat Yerushalmi, Henri Roché, Young‐Hyuck Im, W. Eiermann, Ruben G.W. Quek, Tiziana Usari, Silvana Lanzalone, Akos Czibere, Joanne L. Blum, Miguel Martín, Johannes Ettl - Annals of Oncology 2020 cited by 394

  17. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    Authors: Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans, Kyung Hae Jung, Chiun‐Sheng Huang, Alastair M. Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Matthias W. Beckmann, Karen Afenjar, Rodrigo Fresco, Hans‐Joachim Helms, Jin Xu, Yvonne G. Lin, Joseph A. Sparano, Dennis J. Slamon - The Lancet Oncology 2017 cited by 529

  18. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

    Authors: Nancy U. Lin, Rashmi K. Murthy, Vandana G. Abramson, Carey K. Anders, Thomas Bachelot, Philippe L. Bédard, Virginia F. Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen A. Gelmon, Gabriel N. Hortobágyi, Sara A. Hurvitz, Ian E. Krop, Sherene Loi, Sibylle Loibl, Volkmar Müller, Mafalda Oliveira, Elisavet Paplomata, Mark D. Pegram, Dennis J. Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric P. Winer - JAMA Oncology 2022 cited by 197

  19. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

    Authors: Aditya Bardia, Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O' Shaughnessy, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See‐Chun Phan, Sara A. Hurvitz - Journal of Clinical Oncology 2024 cited by 153

  20. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

    Authors: Giuseppe Curigliano, Volkmar Müller, Virginia F. Borges, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Rashmi K. Murthy, Alicia Okines, E. Paplomata, David Cameron, Lisa A. Carey, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Jorge Ramos, Wentao Feng, Eric P. Winer - Annals of Oncology 2021 cited by 210

  21. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

    Authors: Dennis J. Slamon, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Miguel Martín, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, Fran Visco, Rodrigo Fresco, Tetiana Taran, Gabriel N. Hortobágyi - Journal of Clinical Oncology 2023 cited by 139

  22. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    Authors: Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky - npj Breast Cancer 2022 cited by 103

  23. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

    Authors: M.P. Goetz, M. Toi, Jens Huober, J. Sohn, Olivier Trédan, I.H. Park, Mario Campone, Shyr‐Chyr Chen, Luis Manual Manso, Shani Paluch–Shimon, Orit Freedman, Joyce O’Shaughnessy, Xavier Pivot, S.M. Tolaney, Sara A. Hurvitz, Antonio Llombart‐Cussac, Valérie André, Abhijoy Saha, Guido Van Hal, Ashwin Shahir, Hiroaki Iwata, S. Johnston - Annals of Oncology 2024 cited by 206

  24. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

    Authors: Sara A. Hurvitz, Miguel Martín, Kyung Hae Jung, Chiun‐Sheng Huang, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Peter A. Fasching, Karen Afenjar, Gonzalo Spera, Vanesa López-Valverde, Chunyan Song, Peter C. Trask, Thomas Boulet, Joseph A. Sparano, W. Fraser Symmans, Alastair M. Thompson, Dennis J. Slamon - Journal of Clinical Oncology 2019 cited by 248